Higher tumor mutation burden (TMB) and somatic mutation rates are associated with increased anticancer immunity and greater potential for benefiting from programmed cell death 1/programmed cell death ligand 1 (PD-1/PD-L1) immune checkpoint inhibitors (ICIs). Here, PDCD1 is linked to neoplasm.